articleTop 1% cited

Neuroendocrine Carcinomas of the Colon and Rectum

Diseases of the Colon & Rectum · 2004 · Vol. 47(2) · pp. 163–169

Paul E. Bernick✉David S. Klimstra(Memorial Sloan Kettering Cancer Center)Jinru Shia(Memorial Sloan Kettering Cancer Center)Bruce D. Minsky(Memorial Sloan Kettering Cancer Center)Leonard B. Saltz(Memorial Sloan Kettering Cancer Center)Wei Shi(Memorial Sloan Kettering Cancer Center)Howard T. Thaler(Memorial Sloan Kettering Cancer Center)José G. GuillemPhilip B. PatyA. M. CohenW. Douglas Wong

View via DOI Publisher page

Abstract

Neuroendocrine carcinomas of the colon and rectum are uncommon, comprising less than 1 percent of colon and rectal cancers. Pathologically, these tumors are poorly differentiated carcinomas with distinctive cytoarchitectural features and are often immunoreactive for markers of neuroendocrine differentiation. The prognosis for high-grade neuroendocrine carcinomas is poor, as most patients have metastatic disease at the time of diagnosis.

Colorectal and Anal Carcinomas Neuroendocrine Tumor Research Advances Metastasis and carcinoma case studiesMedicineRectumSurgical oncologyColorectal surgeryGeneral surgeryInternal medicineOncologyAbdominal surgery

MeSH terms

AdultAgedAged, 80 and overBiopsyColonic NeoplasmsFemaleHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPrognosisRectal NeoplasmsRetrospective StudiesBiomarkers, Tumor

Citations

337

FWCI

12.63

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Mixed Adenoneuroendocrine Carcinomas (MANECs) of the Gastrointestinal Tract: An Update